WQ 3330
Alternative Names: WQ 3331Latest Information Update: 17 Oct 2007
At a glance
- Originator Wakunaga Pharmaceutical
- Class Antibacterials; Quinolones
- Mechanism of Action DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 17 Oct 2007 Discontinued - Preclinical for Bacterial infections in Japan (unspecified route)
- 30 Apr 2001 WQ 3330 is available for licensing worldwide (http://www.wakunaga.co.jp)
- 15 Nov 1999 Preclinical development for Bacterial infections in Japan (Unknown route)